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FDA, CLIA, or a "Reasonable
Combination of Both": Toward
Increased Regulatory Oversight of
Genetic Testing
By DOUGIAS A. GRIMM*
GENETIC TESTING-testing a person's genetic makeup for
glimpses into future health-is probably the most rapidly growing
field of laboratory testing in the world. The idea that a great majority
of diseases have their roots in genetics is increasingly popular, leading
many to seek out genetic testing.' The field has enormous importance
as "a person's genetic information is the blueprint to their very be-
ing"2 and is "certainly the language of nature and all living things. '3
But the phenomenal growth of genetic testing has led some to de-
scribe the field as in a "research stage," where the actual benefits of
testing are still being uncovered and understood.4
However, some potential benefits have emerged, including the
possibility of early intervention for treatment of a disease, the elimina-
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1. See Gail H. Javitt et al., Direct-to-Consumer Genetic Tests, Government Oversight, and the
First Amendment: What the Government Can (and Can't) Do to Protect the Public's Health, 57
OKLA. L. REv. 251, 256 (2004).
2. Brian DeBose, Senate Votes to Ban Bias Based on Genetic Makeup, WASH. TIMES, Feb.
18, 2005, available at http://www.washingtontimes.com/functions/print.php?StoryID=200
50217-1148109747.htm (quoting Sen. Christopher J. Dodd).
3. Mark Terry, Spiraling Through Genetic History, http://www.mark-terry/
advgenhx.htm (last visited Aug. 17, 2006).
4. See Octavi Quintana-Trias, Preface to SOCIETY AND GENETIC INFORMATION: CODES
AND LAWS IN THE GENETIC ERA 17 (Judit Sandor ed., Central European University Press
2003). "Human genetics is at a research stage .... There is no doubt that today genetics is
the cornerstone for advances in the life sciences; but the benefits of human genetic re-
search are not yet clearly perceived." Id.
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tion of uncertainty for an individual with a family history of disease,
and the proliferation of information on the possible courses a disease
may take as well as on the potential benefits or risks of a certain course
of treatment.5 While the actual direct physical risk of genetic testing is
minimal, more generalized risks include social, economic, and psy-
chological damage. The potential for a false positive or a false nega-
tive result can have dramatic effects on an individual. For instance, the
individual may decide to undergo or abstain from surgical or other
medical intervention. 6 These decisions carry their own emotional and
psychological burdens. Further, testing can create social risks through
discrimination based on testing results.7
Due to the rapid scientific advances and general popularity of ge-
netic testing, it has proven difficult to set guidelines and rules for the
analysis of genetic data." Genetic and non-genetic tests continue to
receive the same level of oversight from the federal government.9 Ge-
netic tests are primarily regulated by the Food, Drug, and Cosmetic
Act ("FDCA") and the Clinical Laboratory Improvement Amendment
of 1988 ("CLIA").I 0 When considering a genetic test as a product for
use in diagnosis of a condition, the Food and Drug Administration
("FDA")' 1 has authority through the FDCA. When considering a ge-
netic test as a commercial service available through a commercial lab-
oratory, the Center for Medicare and Medicaid Services ("CMS") has
5. See SEC'Y's ADVISORY COMM. ON GENETIC TESTING, NAT'L INSTS. OF HEALTH, EN-
HANCING THE OVERSIGHT OF GENETIC TESTS: RECOMMENDATIONS OF THE SACGT 7 (2000),
available at http://www4.od.nih.gov/oba/sacgt/reports/oversight-report.pdf [hereinafter
SEC'Y's ADVISORY COMM.].
6. See id.
The person who learns of susceptibility or predisposition towards a condition like
heart disease may adapt a lifestyle with a preventative effect. Another person
might enjoy a false sense of security after "testing negative" for the presence of a
particular genotype, only to suffer from the condition in the future.
Phyllis Griffin Epps, Thoughts on the Prospect of Elective Comprehensive Genome Screening, Dec.
23, 2002, http://www.law.uh.edu/healthlawperspectives/Genetics/021223Thoughts.html.
7. See SEC'V's ADVISORY COMM., supra note 5, at 8.
8. SeeJudit Sandor, Genetic Information: Science, Society, and Legal Norms, in SOCIETY AND
GENETIC INFORMATION: CODES AND LAws IN THE GENETIC ERA 22 (Judit Sandor ed., Central
European University Press 2003). Some say it more directly: that there is "little federal
regulatory oversight of genetic tests ... in the United States." SeeJavitt et al., supra note 1,
at 273.
9. See SEC'Y's ADVISORY COMM., supra note 5, at 8.
10. Laura Sternesky, Oversight of Genetic Testing, 11 GENETICS BRIEF, Jan. 2002, at 1,
http://www.ncsl.org/programs/health/genetics/Oversight.pdf.
11. It is common practice among health lawyers to refer to the Food and Drug Ad-
ministration as "FDA" and not "the FDA." Thus, the article "the" will not precede "FDA"
for the remainder of the text unless quoted material contains it.
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authority through CLIA. However, problems with this system arise be-
cause "[t] he ambiguity about the legal status of genetic testing, as well
as arguably underzealous exercise of available authority ... has led to
insufficient oversight of genetic testing."12
That there is "no governmental review of whether [genetic] tests
work or the claims made for them are accurate""' compounds these
problems, especially given FDA's regulation of other laboratory test-
ing.' 4 With the absence of clear criteria for gauging the accuracy of
genetic tests, providers and patients face the risk that errors have oc-
curred in the testing process. 15 Adding to the confusion, not only do
physicians and hospitals provide genetic testing, but commercial labo-
ratories also market genetic testing directly to consumers.' 6
Today, there are more than 1100 genetic diseases and conditions
that genetic testing can uncover-twice that of five years ago. 17 With
over 500 laboratories performing tests, it should come as no surprise
that there are an increasing number of mistakes.' 8 These errors can
have horrific consequences for the patient and family, and more
could be done to avoid them.
This Article examines the current regulatory scheme for genetic
testing and calls for a unification of the testing standards. It advocates
consolidating the standards under a single governmental agency,
FDA, in order to ameliorate the potential for immediate and future
harm to patients and their families. In order to be effective, future
regulations must apply to all providers of genetic testing and create
meaningful, reasonable criteria for testing processes and outcomes.
Moreover, failure to meet these criteria must result in a market ban
for those genetic tests.19 Because it is ever more evident that "the rap-
12. SeeJavitt et al., supra note 1, at 268.
13. Id. at 271-73.
14. Id. at 273.
15. See Am. C. OF MED. GENETICS, STANDARDS AND GUIDELINES FOR CLINICAL GENETICS
LABORATORIES (2003), available at http://www.acmg.net/Pages/ACMG_ Activities/stds-
2002/stdsmenu-n.htm.
16. Javitt et al., supra note 1, at 271. "While the majority of clinical laboratories market
their services primarily, if not exclusively, to physicians and health care institutions, there is
no federal prohibition on marketing genetic tests directly to consumers." Id.
17. See Ariana Eunjung Cha, Labs Turn DNA into Personal Health Forecasts, WASH. POST,
Apr. 7, 2005, at A01.
18. GENETIC TESTING TASK FORCE, PROMOTING SAFE AND EFFECTIVE GENETIC TESTING IN
THE UNITED STATES ch. 3 (1997), http://www.genome.gov/10001733.
19. See George C. Cunningham, A Public Health Perspective on the Control of Predictive
Screeningfor Breast Cancer, 7 HEALTi-I MATRIX 31, 33 (1997) ("To ensure safety, effectiveness,
and necessity, federal and state public health agencies must ensure that screening tests
satisfy reasonable criteria.").
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idly expanding field of genetic testing is not everything its gleaming
molecular image would suggest,"20 reorganizing the system is a
necessity.
I. The Importance and Availability of Genetic Testing
A genetic test is an analysis performed on human DNA, RNA,
genes, and/or chromosomes to detect heritable or acquired ge-
notypes, mutations, phenotypes, or karotypes that cause or are
likely to cause a specific disease or condition. A genetic test also is
the analysis of human proteins and certain metabolites, which are
predominantly used to detect heritable or acquired genotypes, mu-
tations, or phenotypes. 21
Genetic tests are used for "predicting risks of disease, screening
of newborns, directing clinical management, identifying carriers [of a
disease], and establishing prenatal or clinical diagnoses or prognoses
in individuals, families, or populations." 22 The results of these tests
"inform individuals, or at least are perceived as informing individuals,
about their destiny in a way that other medical information does
not."23 One popular perception is that they can predict the future.
The tests work by "[probing] for tiny alterations in crucial genes," 24
and they "can predict, with varying degrees of reliability, a healthy
adult's odds of succumbing to a deadly disorder later in life, in some
cases providing an opportunity to prevent the disease." 25 Embryonic
testing has also become common. The results of this type of genetic
testing can have an enormous effect on a woman's decision to carry a
pregnancy to term or to have an abortion. 26
There are several reasons for a provider to order a genetic test.
These include: identifying the potential for genetic disease, testing
embryos for genetic defects, establishing or confirming diagnoses, de-
termining if there is a potential for future increased disease risk, or
20. Rick Weiss, Genetic Testing's Human Toll: In Unregulated Field, Errors Can Upend Lives
and Mean Unneeded Surgery, WASH. POST, July 21, 1999, at Al. The article describes the
experience of a woman who underwent surgery for removal of her ovaries based on the
results of a genetic test. Eight months later, the testing company informed her that the test
result was incorrect-she had no disposition to ovarian cancer. "Everybody had believed
that this information was so true, and I'd had this surgery based on it, and I'd lived for the
past eight months with this horror and anxiety and all the trauma of how to tell the kids. I
felt like I'd been forced to confront my own death prematurely." Id.
21. See SEC'Y's ADVISORY COMM., supra note 5, at 1.
22. Id. at 1-2.
23. SeeJavitt et al., supra note 1, at 262.
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determining medication responses.97 Further, there are several differ-
ent types of genetic testing. Individuals can undergo diagnostic testing
to identify diseases and to predict the course of the disease and the
effectiveness of treatment modalities. 28 Carrier testing can identify the
potential for a genetic disease, and physicians usually recommend it
for patients who are pregnant or planning a pregnancy. 29 Prenatal
tests can detect genetic defects in embryos, and they are often con-
ducted through ultrasound or blood analysis.30 Preimplantation ge-
netic diagnosis detects genetic defects in an embryo created through
in vitro fertilization.3 1 Using this type of testing, infants can be
screened for genetic defects in order to provide early treatment for
the condition.32 Finally, pharmacogenetic testing can predict the type
of response an individual will have to a specific drug.33
Most genetic tests must be ordered by a health care provider; they
are not directly available to members of the public.3 4 However, a re-
cent study revealed the existence of over one hundred websites offer-
ing genetic testing directly to the public.3 5 The types of services "range
from 'mainstream' genetic tests, or those generally accepted and used
as part of patient care, to those that do not have a history of clinical
use or the usual indicia of scientific support."36
Counseling and interpretation of genetic tests by a qualified pro-
vider is essential. 37 Otherwise, there is no one to explain the meaning
of the test results. 38 Specifically, there is no one to explain to the pa-
tient that a single gene may be associated with more than one disease,
that genes can alter each other, or that the presence of a mutated
27. Javitt et al., supra note 1, at 257.
28. Id. at 259.
29. Id. at 258-59.
30. Id.
31. Id.
32. Id. at 259.
33. Id. at 260.
34. Id. at 262 ("The major laboratories generally sell their testing services to health
care providers and hospitals and not directly to consumers.").
35. Id.
36. Id. at 263. "Mainstream" tests included tests for sickle-cell anemia and cystic fibro-
sis. Other less-accepted tests included genetic profiling, tests to detect possible addictive
behavior, and tests to match dermatologic products with skin type. Id.
37. While all other laboratory testing also requires interpretation by qualified provid-
ers, the interpretation focuses on a diagnosis of an immediate condition. With genetic
testing, the diagnosis is for a condition that might not actually exist, but if it does, it lies in
the future.
38. SeeJavitt et al., supra note 1, at 265. Other concerns include the overall validity of
the tests and the "lack of sufficient information for pretest decision-making." Id.
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gene might not result in the indicated disease or condition. 9 Further,
patients must be reminded that genetic test results only deal with
probabilities of risk.40
Thus, a ninety-nine percent chance of contracting a certain dis-
ease also means that there is a one percent chance that the disease will
not occur. What one cannot predict from the test is "f[w]hether a per-
son who tests positive will manifest the disease, and how severe the
disease will be.''4t However, patients may not receive this crucial ad-
vice from genetic labs that directly market to consumers via the in-
ternet-at times creating unwarranted fear and anguish.42 For this
reason, some critics are calling for an individual ban on each com-
pany offering genetic testing through the internet-at least until the
company proves that counseling and interpretation by a qualified pro-
vider accompany the test results. 43
H1. Regulation of Genetic Tests by FDA
A. A Brief History of FDA
The United States Food and Drug Administration is the oldest
federal regulatory agency, and many consider it to be "our most vener-
able and respected regulatory institution. ' '44 It is also considered one
of the most important agencies of the federal government, as it regu-
lates five categories of products: cosmetics, food, therapeutic drugs,
medical devices, and dietary supplements. 45
The roots of the agency date back to 1862, when the Division of
Chemistry was created as a subset of the United States Department of
39. Sternesky, supra note 10, at 1. There is no one to counsel or advise the patient on
"the method and type of testing; the purpose of the test; the validity of the test; the authori-
zation to order a genetic test; the entities responsible for informed consent; the laboratory
personnel requirements; and the regulatory requirements for different types of laborato-
ries." Id.
40. SeeJavitt et al., supra note 1, at 265.
41. Id.
42. See id. "While the majority of clinical laboratories market their services primarily, if
not exclusively, to physicians and health care institutions, there is no federal prohibition
on marketing genetic tests directly to consumers." Id. at 271. The complex nature of ge-
netic information is not explained, risks and limitations are not adequately disclosed, tests
that lack clinical utility or validity are marketed, and there is no counseling regarding the
results. See id. at 265.
43. See id. at 265-67.
44. LARS NOAH & BARBARA A. NOAH, LAW, MEDICINE, AND MEDICAL TECHNOLOGY 5
(2002) (quoting Peter Barton Hutt, The Transformation of United States Food and Drug Law,
60J. ASs'N FOOD & DRUG OFFICIALS 9, 30 (1996)).
45. Richard Merrill, FDA Reglatoy Requirements as Tort Standards, 12J.L. & POL'Y 549,
550, 552 (2004).
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Agriculture ("USDA"). 46 At the time, there were no laws on the books
for the Chemistry Division to enforce, so it analyzed the food supply
and provided advice to other parts of the USDA on agricultural chem-
istry.47 In 1906, Congress passed the Federal Food and Drugs Act,
which created FDA.48 That legislation was followed in 1938 by the Fed-
eral Food, Drug, and Cosmetic Act, which created statutory authority
for FDA to regulate the manufacture and sale of foods, drugs, and
cosmetics, making it the first agency charged with citizen protection. 41)
In 1953, FDA made its final move away from the Department of Agri-
culture to the Department of Health and Human Services, where it
remains today. 50
The 1938 FDCA has been amended frequently to narrow the
broad scope that the originally drafted statute had. The original act
contained provisions that were written as mandates-not as opera-
tional rules or guidelines for FDA.51 Yet, in the last thirty years, Con-
gress has not engaged in a comprehensive review of the Act, choosing
instead to revise it provision by provision.5 2 Thus, the Act has slowly
become inconsistent in both its terms and scope. Specifically,
"[d]ifferent words are used to mean the same thing in different parts
of the statute, different types of authority are granted with respect to
similar matters, different enforcement powers are provided for com-
parable violations, and the relationship among all of the provisions in
the statute is increasingly ambiguous."53 But, despite these inconsis-
tencies, the scale of FDA's role continues to expand. Growth in the
food and drug industries has led FDA to regulate one quarter of the
46. See NOAH & NOAH, supra note 44, at 2.
47. See id.
48. See Pure Food and Drugs Act, Pub. L. No. 59-384, 34 Stat. 768 (1906) (codified at
21 U.S.C. §§ 1-15 (1934)) (repealed by 21 U.S.C. § 392(a) (1938)), available at http://
www.fda.gov/opacom/laws/wileyact.htm.
49. See Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040
(1938); PHILIPJ. HILTS, PROTECTING AMERICA'S HEALTH: THE FDA, BUSINESS, AND ONE HUN-
DRED YEARS OF REGULATION 6 (2003).
50. See NOAH & NOAH, supra note 44, at 3, 5.
51. Id. at 3.
52. Id.
53. Id. at 3-4.
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United States economy 54 and to employ approximately 10,000 people
with a budget of $1.7 billion.55
B. An Overview of FDA Oversight of Drugs and Medical Devices
1. The General Premarket Approval Process
A visitor to FDA once recalled seeing a placard in someone's of-




Hard data is necessary because Congress assigned FDA the important
task of regulating pharmaceuticals and medical devices, among other
things.57 The agency regulates through a lengthy and thorough review
process that culminates in the evaluation of a sponsor's New Drug Ap-
plication ("NDA") .58 An NDA functions as the summary document of
all the studies involving the drug or medical device, and it should pro-
vide sufficient information to FDA's investigators for them to deter-
mine if the drug or medical device is safe and effective. 59
Courts have granted great discretion to FDA in promulgating
these premarket approval requirements. 60 The agency's requirements
54. Id. at 5. The value of about one quarter of the United States economy is approxi-
mately $1.5 trillion. See Eve E. Slater, Today's PDA, 352 NEW ENG. J. MED. 293, 293 (2005);
THE FOOD AND DRUG ADMINISTRATION'S STRATEGIC ACTION PLAN: PROTECTING AND ADVANC-
ING AMERICA'S HEALTH: RESPONDING TO NEW CHALLENGES AND OPPORTUNITIES (2003),
http://www.fda.gov/oc/mcclellan/strategic.html [hereinafter ACTION PLAN].
55. See Slater, supra note 54, at 293.
56. Karen Lusky, FDA Puts ASR Rule Back on the Table, CAP TODAY, Oct. 2003, http://
www.cap.org/apps/docs/captoday/feature-stories/CoverFDAputsASRrule.html.
57. See NAT'L CANCER INST., Understanding the Approval Process for New Cancer Treatments,
Jan. 6, 2004, http://www.nci.nih.gov/clinicaltrials/learning/approval-process-for-cancer-
drugs.
58. See 21 U.S.C. § 355(b)(1) (2000).
[A sponsor] shall submit to the Secretary as a part of the application (A) full
reports of investigations which have been made to show whether or not such drug
is safe for use and whether such drug is effective in use; (B) a full list of the
articles used as components of such drug; (C) a full statement of the composition
of such drug; (D) a full description of the methods used in, and the facilities and
controls used for, the manufacture, processing, and packing of such drug; (E)
such samples of such drug and of the articles used as components thereof as the
Secretary may require; (F) specimens of the labeling proposed to be used for
such drug.
Id.
59. CTR. FOR DRUG EVAL. AND RES., NEW DRUG APPLICATION PROCESS (2005), http://
www.fda.gov/cder/regulatory/applications/NDA.htm.
60. See Edison Pharm. Co. v. FDA, 600 F.2d 831 (D.C. Cir. 1979), discussed in DavidJ.
Wu, A Pharmacogenomics Standard for FDA Drug Approval: Arbitrary and Capricious or Safe and
Effective?, 23 BIOTECH. L. REP. 733, 738 (2004). In this case, the agency's requirement of a
double-blind controlled study was challenged by a drug manufacturer. Wu, supra at 738.
The court upheld the requirement as an appropriate measure of the agency's discretion to
ensure the safety and effectiveness of a product. Id. "The FDA may refuse [product] ap-
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for premarket approval are thus specific and substantial. FDA esti-
mates that it takes approximately eight-and-a-half years to study and
test a new drug before it can be approved for the general public. 6'
Other sources estimate that the approval process is much longer and
more expensive. According to a Pharmaceutical Research and Manu-
facturers of America estimate, a mere one out of every five thousand
medicines tested is eventually approved for patient use.62 Moreover, it
takes twelve to fifteen years to bring a new medicine to market, and
"the average cost of doing so is $800 million."63
FDA has a couple of primary objectives during the approval pro-
cess. On the one hand, the agency aspires to ensure that a treatment is
safe and effective. 64 On the other hand, the agency tries to "make
promising treatments available as quickly as possible to the people
most in need of them."65 To meet these two objectives, FDA must
make three critical determinations during the approval process. First,
it must determine if the benefits of a treatment are outweighed by the
risks. Second, it must continue monitoring progress reports from
clinical trials to ensure that the treatment is effective. Last, upon con-
clusion of the clinical trials, it must determine "whether or not the
treatment should be sold to the public and, if so, what claims the drug
manufacturer can make and what the label should say about direc-
tions for use, side effects, and warnings." 66
FDA requires that a drug sponsor submit data on safety prior to
beginning the first phase of clinical studies. Sponsors can comply in
several ways, but they usually do so by submitting data on laboratory
proval if the developer submits 'insufficient information to determine whether the [prod-
uct] is safe."' Id. at 739.
61. CTR. FOR DRUG EVAL. AND RES., Synthesis and Purifications, in THE CDER HANDBOOK
5-6 (1998), available at http://www.fda.gov/cder/handbook/.
62. Todd A. Rosenfield, Comment, The Counterfeit Drug Invasion: How Drug Reimporta-
tion Unjustifiably Poses a Threat to the Health of the U.S. Public, 25 U. PA. J. INT'L ECON. 1047,
1049-50 (2004).
63. Id.; see also FDA OFF. OF PUB. AFF., FDA AND THE DRUG DEVELOPMENT PROCESS:
HOW THE AGENCY ENSURES THAT DRUGS ARE SAFE AND EFFECTIVE (2002), available at http://
www/fda.gov/opacam/factsheets/j ustthefacts/17drgdev.pdf. "[T]he process of bringing a
drug to a patient's bedside takes an average of 8.5 years, costs about $500 million ..... Id.
64. "'Safe' does not mean that the treatment is free of possible adverse side effects;
rather, it means that the potential benefits have been determined to outweigh any risks."
See NAT'L CANCER INST., supra note 57. See also CTR. FOR DRUG EVAL. AND RES., Clinical
Studies (Overview), in THE CDER HANDBOOK, supra note 61, at 7. "Although the goal of
clinical trials is to obtain safety and effectiveness data, the overriding consideration in these
studies is the safety of those in the trials." Id.
65. See NAT'L CANCER INST., supra note 57.
66. Id.
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and animal studies.67 In these studies, sponsors seek to develop a
pharmacological profile of the drug and to determine toxicity of the
drug in at least two species of animals. 68 The purpose of the studies "is
to develop adequate data to undergird a decision that it is reasonably
safe to proceed with human trials of the drug."69
The studies on animals measure the degree of the drug's absorp-
tion into the blood, its chemical breakdown, its toxicity, and the speed
in which the drug passes from the body.70 Animal testing can last from
several weeks to several years, depending on the intended use of the
drug. In some situations, such as the use of oncologic drugs, testing
may continue after human trials have begun in order to determine if
cancer or birth defects will result from the use of the drug.7' If animal
lab tests are favorable, the sponsor files an Investigational New Drug
("IND") application with the Center for Drug Evaluation and Re-
search ("CDER") or the Center for Biologics Evaluation and Research
("CBER"). 72 If the CDER or the CBER grants the IND, then the com-
pany may begin clinical trials under the supervision of FDA.73 Human
testing cannot begin without FDA approval,7 4 and only one out of a
thousand chemical compounds passes the animal studies stage to go
on to human trials. 7 5
Human clinical trials have three phases. In Phase I treatment tri-
als, a small number of volunteer patients (usually between fifteen and
thirty) are given the experimental treatment in gradually larger doses
to test for any side effects or complications, as well as to determine a
67. CTR. FOR DRUG EVAL. AND RES., Pre-clinical Research, in THE CDER HANDBOOK, supra
note 61, at 5. Two other methods for compliance are compiling data from previous clinical
testing or marketing of the drug in the United States or another country whose population
is relevant to the United States population; or undertaking new preclinical studies de-
signed to provide the evidence necessary to support the safety of administering the com-
pound to humans. Id.
68. See CTR. FOR DRUG EVAL. AND RES., Pre-clinical Research, in THE CDER HANDBOOK,
supra note 61, at 5. Two species, rodent and non-rodent, are tested to ensure uniformity of
drug interaction. See also CTR. FOR DRUG EVAL. AND RES., Animal Testing, in THE CDER
HANDBOOK, supra note 61, at 6.
69. See CTR. FOR DRUG EVAL. AND RES., Institutional Review Boards, in THE CDER HAND-
BOOK, supra note 61, at 6-7.
70. See CTR. FOR DRUG EvAL. AND RES., Animal Testing, in THE CDER HANDBOOK, supra
note 61, at 6.
71. See CTR. FOR DRUG EvAL. AND RES., Short Term Testing, in THE CDER HANDBOOK,
supra note 61, at 6; CTR. FOR DRUG EvAL. AND RES., Long Tenn Testing, in THE CDER HAND-
BOOK, supra note 61, at 6.
72. See 21 C.F.R. § 312.42 (2000).
73. See NAT'L CANCER INST., supra note 57.
74. Id.
75. FDA OFF. OF PUB. AFF., supra note 63.
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safe dose of the treatment. 76 Phase II treatment trials test the effective-
ness of the drug and usually involve several hundred patients.77 Fol-
lowing Phase II trials, a decision must be made whether to proceed
with Phase III testing.78 Protocols are developed, specific data is ex-
changed, and an agreement is reached between FDA and the treat-
ment sponsor regarding the plan and design of the study. 79 Phase III
trials begin after the agreement is reached.8 0 These trials seek to de-
termine the "overall benefit-risk relationship of the drug," both stand-
ing alone and in relation to existing treatments.8 ' Participation can
vary from several hundred to several thousand subjects. 8 2
If the clinical trials show that the treatment is safe and effective,
then the company or sponsor submits a New Drug Application to
FDA.8 3 The NDA is the "vehicle through which ... sponsors formally
propose that FDA approve a new pharmaceutical for sale in the
United States."8 4 The NDA must include: the exact chemical makeup
of the drug; results of animal studies; results of clinical trials; the
method by which the drug is made, processed, and packaged; and the
standards used for quality control.8 5 FDA works towards a ten-month
review period of the NDA. But that time period has actually ranged
from forty-two days to several years.8 6
76. See CTR. FOR DRUG EVAL. AND RES., Phase I Clinical Studies, in THE CDER HAND-
BOOK, supra note 61, at 8. "Phase 1 studies.., evaluate drug metabolism structure-activity
relationships, and the mechanism of action in humans. These studies also determine
which investigational drugs are used as research tools to explore biological phenomena or
disease processes." Id.
77. See CTR. FOR DRUG EVAL. AND RES., Phase 2 Clinical Studies, in THE CDER HAND-
BOOK, supra note 61, at 8. "Phase 2 includes the early controlled clinical studies conducted
to obtain some preliminary data on the effectiveness of the drug for a particular indication
or indications in patients with the disease or condition." Id.
78. See CTR. FOR DRUG EVAL. AND RES., Sponsor-FDA Meetings (End of Phase 2), in THE
CDER HANDBOOK, supra note 61, at 10.
79. Id. at 10-11. The sponsor must provide the following to FDA: "data supporting the
claim of the new drug product, chemistry data, animal data and proposed additional
animal data, results of Phase 1 and 2 studies, statistical methods being used, specific proto-
cols for Phase 3 studies, as well as a copy of the proposed labeling for a drug, if available."
Id.
80. See CTR. FOR DRUG EVAL. AND REs., Phase 3 Clinical Studies, in THE CDER HAND-
BOOK, supra note 61, at 9.
81. Id.
82. Id.
83. See 21 C.F.R. § 314 (2003).
84. See CTR. FOR DRUG EVAL. AND RES., Clinical Studies (Overview), in THE CDER HAND-
BOOK, supra note 61, at 7.
85. See NAT'L CANCER INST., supra note 57.
86. Id.
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FDA looks at all the data submitted and the results of its own re-
view[;] it applies two benchmark questions to each application: Do
the results of well-controlled studies provide substantial evidence
of the treatment's effectiveness? Do the results show the product is
safe under the conditions of use in the proposed labeling?8 7
Once FDA rules on an NDA, its decision is virtually unchallenge-
able.8 8 If the treatment is approved, CDER's Office of Compliance
provides post-approval monitoring "to make sure that [the sponsor]
complies with current standards and regulations. '89 The Drug Over-
sight Safety Board then monitors drugs approved by FDA to ensure
continuing safety and communication of information to physicians
and patients, to resolve disputes over drug safety, and to develop a
national drug safety policy.9 0
2. FDA Regulation of Genetic Tests
Diagnostic laboratory tests that are sold widely to hospitals, doc-
tors' offices, and commercial laboratories are classified as medical de-
vices by FDA and must go through an FDA approval process. 91
Generally, a medical device is any health care product that does not
achieve its principal intended purposes by chemical action in or on
the body.9 2 "But tests developed by a single laboratory and offered as a
87. See id.; CTR. FOR DRUG EvAL. AND REs., Clinical Studies (Overview), in THE CDER
HANDBOOK, supra note 61, at 7.
88. See Lars Noah, Deputizing Institutional Review Boards to Police (Audit?) Biomedical Re-
search, 25 J. LEGAL MED. 267, 284 (2004). "Patients, physicians, and other interested per-
sons generally have no direct opportunity to ask a court to review an agency decision to
approve or reject an NDA." Id. "Although courts show tremendous deference to the
agency's scientific judgments, the FDA could not revoke a license on a whim or just be-
cause of a shift in the political winds." Lars Noah, A Miscarriage in the DrugApproval Process?:
Mifepristone Embroils the FDA in Abortion Politics, 36 WAKE FOREsT L. Rrv. 571, 592-93 (2001)
(citing Henley v. FDA, 77 F.3d 616, 620-21 (2d Cir. 1996) and Schering Corp. v. FDA, 51
F.3d 390, 399 (3d Cir. 1995)).
89. NAT'L CANCER INST., supra note 57.
90. Laurie Kellman, FDA to Establish New Drug Oversight Board, http://news.yahoo.
com/news?tmpl=story&u=/ap/20050215/apongo_ca st pe/fda_chief13 (last visited
Aug. 17, 2006).
91. Andrew Pollack, FDA Asks if a Genetic Test Is Sold Without Approval, N.Y. TIMES, July
18, 2003, at C2.
92. Food and Drug Administration, Statement of Policy for Regulating Biotechnology
Products, 49 Fed. Reg. 50,878 (Dec. 31, 1984). A more comprehensive definition is
an instrument, apparatus, implement, machine, contrivance, implant, in vitro rea-
gent, or other similar or related article, including a component part, or accessory
which is: ... recognized in the official National Formulary, or the United States
Pharmacopoeia, or any supplement to them.... intended for use in the diagnosis
of disease or other conditions, or in the cure, mitigation, treatment, or preven-
tion of disease, in man or other animals, or... intended to affect the structure or
any function of the body of man or other animals, and which does not achieve
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service by that laboratory do not require such approval, although the
laboratory has to meet certain quality standards. These tests are some-
times known as 'home-brew' tests. '" 9
3
FDA has established some regulations on home-brew tests. For
instance, it regulates the active ingredients used to perform these tests
by classifying the ingredients, known as analyte-specific reagents
("ASRs"), as medical devices. 94 However, the premarket approval pro-
cess described above is not applied to ASRs;95 instead, the reagents
must comply only with "General Controls," which still fall within the
jurisdiction of FDA but face a lower standard. 96 By understanding the
way in which FDA regulates ASRs and home-brew tests, one can begin
to see the problems inherent in the system. Companies are free to
skirt FDA approval process by simply employing home-brew type test-
ing. "Instead of selling a complete test requiring [FDA] approval,
[companies] sell the basic ingredients of a test to clinical laboratories.
The labs then use the ingredients to make home-brew tests."'97 And
the public is none the wiser, as currently FDA does not regulate "[the]
communications made by the laboratories providing genetic tests, or
the manner in which such tests are sold or provided to patients."9 8
any of its primary intended purposes through chemical action within or on the
body of man or other animals and which is not dependent upon being metabo-
lized for the achievement of any of its primary intended purposes.
Food and Drug Administration, Ctr. for Devices and Radiological Health, Is the Product a
Medical Device?, http://www.fda.gov/cdrh/devadvice/312.html (last visited Aug. 17,
2006).
93. See Pollack, supra note 91, at C2.
94. See Javitt et al., supra note 1, at 272-73; Sternesky, supra note 10, at 1-2. ASRs
typically are chemicals or pieces of DNA. See Pollack, supra note 91.
95. See supra Part IBI.B.1.
96. SeeJavitt et al., supra note 1, at 273. General Controls are the basic provisions of
the Amendments to the Food, Drug, and Cosmetic Act that provide FDA with the means of
regulating devices to ensure their safety and effectiveness. See also Food and Drug Adminis-
tration, General Controls for Medical Devices, http://www.fda.gov/cdrh/devadvice/
363.html (last visited Aug. 17, 2006). General Controls apply to all medical devices, but are
the only level of regulation for Level I devices. Id. Level I devices are the least complex
devices regulated by FDA. See id. Examples of Class I devices include elastic bandages, ex-
amination gloves, and hand-held surgical instruments. See CDA Design Group, FDA Regu-
latory Requirements and Approvals, http://www.cdaservices.com/fdaapproval.htm (last
visited Aug. 17, 2006). It is difficult to lump the safety issues surrounding genetic testing in
with safety issues regarding latex gloves or an ACE bandage.
97. See Pollack, supra note 91. But it seems that it is a fine line these companies walk.
"Roche, one of the leaders in the diagnostic testing business, is marketing its gene-chip test
in such a way. But the [FDA] said the test appeared to be a complete medical device that
should have gone through the regulatory approval process." Id.
98. SeeJavitt et al., sura note 1, at 273.
Fall 2006] REGULATION OF GENETIC TESTING
UNIVERSITY OF SAN FRANCISCO LAW REVIEW
Thus, the current approach results in a bipolar system. The rigor-
ous, methodical analysis required for the approval of new drugs, de-
vices, or other blood tests is easily bypassed for genetic testing through
the use of home-brew tests. This system leaves "commercial biotech-
nology companies and other laboratories, which already are offering
more than 400 genetic tests to a largely uneducated public, . .. free to
decide how accurate their tests need to be before marketing them and
what they will say in their advertisements to doctors and others."99
What is the response? FDA currently states that "it lacks the resources"
to regulate genetic tests.100
III. Regulation of Genetic Tests Under CLIA
The Clinical Laboratory Improvement Amendment of 1988 is the
other primary means of regulating genetic tests at the federal level. In
1988, Congress was not yet focused on genetic testing. Instead, Con-
gress passed CLIA as a response to increasing public concern over the
quality of clinical laboratory testing in general. 10 The Center for
Medicare and Medicaid Services implements CLIA, which applies to
approximately 175,000 laboratories' 0 2 and sets quality standards de-
signed to assure the reliability and accuracy of test results.' 0 3 Under
CLIA, the CMS and the Center for Disease Control's ("CDC") Division
of Laboratory Systems "develop[ ] standards for laboratory certifica-
tion."' 0 4 The standards require laboratories to undergo on-site inspec-
tions biannually, and the inspections cover the environment of the
lab, the competency of the personnel, as well as quality control and
99. See Weiss, supra note 20.
100. Id. And this might very well be true.
In comparison with other government agencies, the FDA is tiny. It constitutes less
than one half of one percent of the federal government's [two] million work-
ers . . . .Over the years, tasks have been routinely assigned to the agency by
Congress without the funds to carry them out, so a central problem of the agency
over the past century has been to spread the very limited budget over an increas-
ing array of jobs.
HILTS, supra note 49, at xv.
101. See 42 U.S.C. § 1395x (2000); Clinical Laboratory Improvement Amendments of
1988, Pub. L. No. 100-578, 102 Stat. 2903 (1988); 42 C.F.R. § 493.1 (2000); 57 Fed. Reg.
7002-03 (2000); see also Morton K. Schwartz, Genetic Testing and the Clinical Laboratory Im-
provement Amendments of 1988: Present and Future, 45 CLINICAL CHEMISTRY 739, 739 (1999).
102. CTRS. FOR MEDICARE AND MEDICAID SERVICES, CLIA PERSPECTIVE HIV RAPID
TEST CONSULTATION (2004), available at http://www.cdc.gov/hiv/pubs/rt/G-Yost.pdf.
103. SeeJavitt et al., supra note 1, at 268 (quoting H.R. REP. No. 100-899, at 8 (1988),
reprinted in 1988 U.S.C.C.A.N. 3828, 3829); Schwartz, supra note 101, at 739.
104. SEc'Y's ADVISORY COMM., supra note 5, at 9.
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assurance mechanisms.1 5 However, the focus of these inspections is
on "intra-laboratory processes as opposed to the clinical uses of test
results." 16
The standards set by CLIA are substantial, and they provide for
quality control and assurance, proficiency testing, and patient test
management. 117 The quality control standard requires the creation of
manuals to document processes within the lab, the calibration and
validation of instruments, and the written documentation of quality
control activities. 10 8 The quality assurance standard covers the avail-
ability and ordering of tests, the level of patient preparation, the ade-
quacy of specimen collection, and the interpretation of lab results.1 0 9
The patient test management standard involves rules to assure the in-
tegrity and identification of patient specimens during the testing
process. ' 10
However, "CLIA does not address additional aspects of oversight
that are critical to the appropriate use of genetic tests, such as clinical
validity including clinical sensitivity and clinical specificity, clinical
utility, and issues related to informed consent and genetic counsel-
ing."'1 I Clinical test validation is one of the most important quality
assurance measures. 112 As a concept, it determines whether the test
actually works and provides accurate results for the patient. Thus,
clinical test validation seeks to answer some of the real questions
about genetic tests: whether a patient who tests positive for a condi-




107. See 42 C.F.R. § 493.1100 (2000); Schwartz, supra note 101, at 740. See alsoJavitt et
al., supra note 1, at 269 n.108 (quoting 42 U.S.C. § 263a(f)(1) (2000) ("CMS is charged
with 'issuing standards to assure consistent performance... of valid and reliable laboratory
examinations and other procedures."')).
108. See Schwartz, supra note 101, at 740.
109. Id.
110. Id.
111. SEc'v's ADviSORY COMM., supra note 5, at 9. "Clinical validity refers to the accuracy
of the test in diagnosing or predicting risk for a health condition and is measured by the
sensitivity, specificity, and predictive value of the test for a given health condition. Clinical
utility involves identifying the outcomes associated with positive and negative test results."
Id. at 16.
112. SeeAM. C. OF MED. GENETICS, supra note 15. Clinical test validation involves review-
ing the literature available on the test, performing correlation studies, defining the test
limitations, determining the variables that will be monitored to ensure continued accuracy,
addressing any legal, social, or ethical issues, and collecting data on the test procedure and
results in order to best inform providers and patients. Id.
113. See Lusky, supra note 56.
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After the passage of CLIA, the Secretary of Health and Human
Services ("HHS") issued standards for laboratories that included profi-
ciency standards for specific areas such as hematology and cytol-
ogy114-standards that must be met before a test can be performed.
However, even though laboratories that offer genetic testing are sub-
ject to CLIA, CMS has not mandated proficiency testing standards for
genetic testing. 115 Thus, there is no "nationwide proficiency testing or
even licensing process for laboratories that perform genetic tests."'"1 6
IV. The Movement Towards Increased Regulation of Genetic
Tests
A. Clinical Laboratory Improvement Advisory Committee
The 1988 CLIA amendments also created an advisory commit-
tee-the Clinical Laboratory Improvement Advisory Committee
("CLIAC") .117 CLIAC is an ongoing committee, still in existence to-
day. The committee provides non-binding guidance to the Secretary
of HHS. 118 It has twenty members-all of whom have expertise in the
specialties surrounding clinical laboratory testing. 1" 9 The members
are drawn from FDA, the CMS, and the CDC. 120 However, at the time
that CLIAC was formed, genetic testing was in a nascent stage, and it
was not represented by a member on the committee. 121
CLIAC recommendations have addressed staffing, confidentiality
and informed consent, quality control, contamination, proficiency
testing, test validation, record retention, and specimen reuse. 122
114. SeeJavitt et al., supra note 1, at 268-69.
115. See Sternesky, supra note 10 at 1. "While genetic testing laboratories are subject to
CLIA, the amendments offer no genetic-specific regulations other than the cytogenetics
specialty, resulting in limited evaluation and quality assurance oversight." Id.
116. Weiss, supra note 20, at A12. Whether this is because the science is moving at such
a brisk pace or because testing has not been sufficiently prioritized is unclear at this point.
117. See Schwartz, supra note 101, at 740.
118. Id. at 741.
119. Id.
120. JOE BOONE, CTRS. FOR DISEASE CONTROL, DEVELOPMENT OF A GENETIC TESTING SPE-
CIALTY UNDER CLIA (2003), available at http://www4.od.nih.gov/ oba/SACGHS/meet-
ings/October2003/Boone.pdf.
121. See Schwartz, supra note 101, at 741.
122. Id. at 742-44.
Health and Human Services will establish a Clinical Laboratory Improvement Ad-
visory Committee to advise and make recommendations on technical and scien-
tific aspects of the provisions of CLIA. CLIAC will be comprised of individuals
involved in the provision of laboratory services, utilization of laboratory services,
development of laboratory testing or methodology .... CLIAC ... will review and
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CLIAC has also addressed a myriad of areas relating to genetic-testing
procedures. 12.13
But, perhaps due to the absence of an expert on genetic testing
on the committee, CLIAC issued no guidance for the field until 1997.
At that time, a subgroup within the committee produced a strategic
plan for genetic testing that called for the establishment of "standards,
regulations and guidelines to ensure the accuracy, validity and preci-
sion of laboratory procedures [for genetic testing] and to ensure that
other quality assurance issues [were] addressed as well."' 124 Ultimately
CLIAC concluded that a discrete genetic-testing section should be
added to CLIA. 125 The committee members felt that "the high degree
of precision and accuracy required for genetic testing required strin-
gent regulations."' 2 6
CLIAC adopted two definitions of genetic testing-one address-
ing the analysis of DNA, RNA, and chromosomes, the other address-
ing the analysis of proteins and metabolites. 127 Both testing types seek
to "predict[ ] risk of disease, [to] identify[ ] carriers, and [to] estab-
lish[ ] prenatal or clinical diagnos[e] s or prognos[e]s."128 Regulating
these tests was a step in the right direction. Yet, despite this move to-
wards increased specific oversight, CLIAC has made little mention of
regulating test results or of verifying a test's clinical validity.
B. Task Force of the National Human Genome Research Institute
Independent of the direct federal regulatory structures of FDA
and CLIA, the Task Force of the National Human Genome Research
Institute was created in April 1995, primarily by the National Institutes
of Health and the Department of Energy. 129 Its mission was to review
make recommendations concerning: criteria for categorizing tests ... QC, QA
standards ... and other issues relevant to CLIA ....
Id. at 740-41.
123. Id. at 742-44.
124. Id. at 741 (quoting CTRS. FOR DISEASE CONTROL, TRANSLATING ADVANCES IN HUMAN
GENETICS INTO PUBLIC HEALTH ACTION: A STRATEGIC PLAN 24 (1997), available at
www.cdc.gov/genomics/about/strategic.htm).
125. See Schwartz, supra note 101, at 741-42. "This conclusion was based on the fact
that although the testing technology is similar to that used in other laboratory areas, the
sensitivity of genetic testing results and the social, economic, and legal aspects of such tests
require[d] a separate section in CLIA." Id. at 742.
126. Id. at 742.
127. Id.
128. Id.
129. See Nat'l Human Genome Research Inst., Nat'l lnsts. of Health, About the Insti-
tute: A History and Timeline, http://www.genome.gov/10001763 (last visited Aug. 17,
2006).
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genetic testing in the United States and to ensure it was safe and effec-
tive. 130 The Task Force defined safety and effectiveness to include
"not only the validity and utility of genetic tests, but their delivery in
laboratories of assured quality, and their appropriate use by health
care providers and consumers."13' It recognized that, while genetic
testing was a growing field, there were still many things unknown.
For example, there were, and still are, no means by which to alter
or improve conditions caused by inherited diseases. Negative test re-
sults cannot definitively rule out a future occurrence of disease, nor
can a positive test result be relied upon as definitive evidence that a
disease will occur.132 Thus, the Task Force emphasized the need for
regulation, pointing out that some genetic tests were introduced into
the marketplace prior to being proved safe and effective.1 33 It also
highlighted the need for continued monitoring once a test reaches
the marketplace. 134
Further, the Task Force suggested that test developers should
provide data to a primary regulating body in order to develop stan-
dards for routine use.13 5 Ultimately, the Task Force recommended the
formation of a group that could have a more direct effect on the regu-
latory process. That group became the Secretary's Advisory Commit-
tee on Genetic Testing ("SACGT"). 136
C. Secretary's Advisory Committee on Genetic Testing
The Secretary's Advisory Committee on Genetic Testing was
formed by the Secretary of HHS in June 1998. Its purpose was "to
advise the Department of Health and Human Services on the medical,
scientific, ethical, legal, and social issues raised by the development
and use of genetic tests."1 37 SACGT worked on several issues: the crite-
ria used to assess the benefits and risks of genetic testing, how those
criteria could be used to differentiate between tests, how to analyze
and publish data on a test, and how genetic testing could be moni-
130. See Nat'l Human Genome Research Inst., Nat'l Insts. of Health, Promoting Safe
and Effective Genetic Testing in the United States, http://www.genome.gov/10002393




134. See id. "When preliminary data indicate a test is likely to have validity and utility,
the test should be approved for marketing but developers must continue to collect data
until more definitive answers are obtained." Id.
135. See id.
136. See id.
137. SEc'v's ADvIsoRy COMM., supra note 5, at 1.
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tored.' 3 8 SACGT identified several options for oversight of genetic
testing: the strengthening of the current CLIA and FDA regulations,
the formation of interagency review boards, and the formation of pro-
fessional organizations. 39 Public comments on the options yielded a
wide variety of suggestions-one of the more popular being the desig-
nation of FDA as the agency to oversee tests. This suggestion was
adopted by SACGT."41
SACGT also recommended that CLIA regulations be revised for
increased specificity on quality standards for labs,141 and in 1999,
SACGT formally supported CLIAC's recommendations for increased
oversight. 142 In July 2000, SACGT refined its support of CLIAC by sub-
mitting a report to the Secretary of HHS that outlined its recommen-
dations on genetic testing.143 The report called for FDA regulation of
genetic tests, including home-brews. 144 CLIAC/SACGT further at-
tempted to develop a proposed rule for genetic tests by publishing a
Notice of Intent. It announced that HHS would prepare a Notice of
Proposed Rulemaking based on recommendations from CLIAC.t45
The Notice of Intent addressed definitions and categories of ge-
netic testing, clinical validity issues, informed consent, confidentiality,
genetic counseling, as well as pre-analytic, analytic, and post-analytic
issues, which included test requisition, retention, quality control and
proficiency testing, and personnel qualifications and responsibili-
ties."46 It also recommended that the agency's "review processes must
minimize the time and cost of review without compromising the qual-
ity of the assessment of test validity." 147 Public responses to the Notice
of Intent demonstrated that most supported the creation of the spe-
cialty but felt that the proposed definitions were too broad.148
One of the primary questions that emerged was whether a
method could be instituted to assign levels of oversight for a test based
138. Id. at 4.
139. Id. at 25.
140. Id. at 25, 27. "FDA should be the federal agency responsible for the review, ap-
proval, and labeling of all new genetic tests that have moved beyond the basic research
phase .... FDA must delineate review processes for pre-market evaluation of genetic tests."
Id. at 27.
141. Id. at 28.
142. See BOONE, supra note 120.
143. Id.
144. See Pollack, supra note 91 at C2.
145. See CTRS. FOR MEDICARE AND MEDICAID SERVICES, supra note 102.
146. See BOONE, supra note 120.
147. SEC'v's ADVISORY COMM., supra note 5, at x.
148. See BOONE, supra note 120.
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on its characteristics. For example, should a genetic test that is more
complex receive greater oversight than a more basic test? Such a solu-
tion would lead to more efficient use of resources, making it a com-
mon-sense choice for the fast-growing field. Thus, in August 2000,
SACGT submitted an addendum to the July 2000 oversight report that
addressed this classification system.' 49
The committee used four criteria to classify a genetic test: "[T] est
volume; whether the test would be used for population-based testing;
whether the test [was] diagnostic or predictive; and a set of three
questions related to the availability of an intervention, the predictive
value of the test, and potential for medical or social harms associated
with the test."150 The classification methodology was a bifurcated sys-
tem. A test would be assigned to either Scrutiny Level I ("SL I") or
Scrutiny Level II ("SL II") based on values associated with the criteria
above. 1 5 1
However, problems became evident when pilot testing began. For
instance, problems arose with the criterion of test volume "since some
low volume tests, which according to the proposed methodology
would warrant SL I, might have heightened ethical and social implica-
tions that would warrant an SL II review."'1 52 The criteria were there-
fore changed to include analytical validity and disease frequency, and
public comment was sought. 153 The responses that were received
raised significant concerns regarding the ability of the criteria to suc-
cessfully classify genetic testing. SACGT "concluded that fundamental,
irresolvable questions had been raised about the feasibility of catego-
rizing tests for oversight purposes based on a limited set of elements
in a simple, linear fashion"'154 and, thus, "decided that further efforts
to develop a classification methodology for genetic tests should be
149. See SEC'Y'S ADVISORY COMM. ON GENETIC TESTING, NAT'L INSTS. OF HEALTH, DEVEL-
OPMENT OF A CLASSIFICATION METHODOLOGY FOR GENETIC TESTS: CONCLUSIONS AND RECOM-
MENDATIONS OF THE SECRETARY'S ADVISORY COMMITTEE ON GENETIC TESTING 6 (2001),
available at http://www4.od.nih.gov/oba/sacgt/reports/Addendum-final.pdf.
150. Id. Test volume was used for its public health concerns, ensuring that resources
are directed at the population most likely to benefit from the test. Id. Population-based
screening, the second criterion, was defined as "testing of groups or populations of cur-
rently healthy people rather than individuals or families." Id.
151. Id.
152. Id. at 8.
153. Id. Analytical validity was defined as "the ability of a test to measure or detect the
analyte it is intended to measure or detect." Id. at 8. Frequency of disease "divided tests by
whether they tested for a common or rare disease." Id. at 10.
154. Id. at 11.
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curtailed."'15 5 Essentially, SACGT deferred the task of developing a
classification methodology, leaving it to FDA.'15 6
The Secretary's Advisory Committee on Genetics, Health, and So-
ciety recently replaced SACGT, and this new committee is supposed to
"address the broader implications resulting from the development
and application of genetic technologies.1 5 7 However, the current ad-
ministration has tabled SACGT's recommendations pending a new
review.
V. Options for Increased Regulatory Oversight of Genetic
Tests
Taking into consideration the actual progress made towards a
regulatory scheme for genetic testing, or the lack thereof, there are
several basic options that could improve the current system. First, ex-
isting FDA and CLIA regulations could be strengthened. If federal co-
ordination was emphasized, and the agencies were to work in concert,
then the situation would likely progress from its current state. This
would represent an improvement because "CLIA's regulatory tools are
different than those available to the FDA," so "some reasonable com-
bination of both might be used to address the concerns regarding ge-
netic testing."' 58 However, this combination of efforts would create a
significant risk of inefficiency, necessitating that any new regulations
explicitly delineate a focus on interagency cooperation and coordina-
tion in order to ensure that the agencies do not work in parallel. The
agencies would
have to be careful to avoid duplicating oversight efforts[.] For ex-
ample, if CLIA were to do clinical reviews of lab-developed tests,
and the FDA did some form of premarket reviews, that's double
work. Also, CLIA oversees labs, not manufacturers. And when a lab
takes an ASR and creates a new test system, the lab becomes a man-
ufacturer. CLIA is not really intended to oversee that
[function] .159
A second option is to place regulation of genetic tests under the
sole purview of FDA. As detailed above, FDA's experience regulating
all other types of laboratory tests, as well as foods and drugs, makes it
well-equipped to implement CLIAC's recommendations for genetic
155. Id.
156. See id.
157. Suzanne Cox et al., International Genetic Testing, 5 GENETICS IN MED. 176, 178
(2003). See also Epps, supra note 6.
158. Lusky, supra note 56.
159. Id.
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testing. If FDA lacks the resources to regulate genetic tests, then the
needed resources should be allocated to FDA.' 60 Further, by overlay-
ing some of the ongoing monitoring programs, which FDA currently
maintains for drugs and medical devices, the quality of genetic-testing
results would arguably be improved. A larger, more comprehensive,
and current system of monitoring could eclipse the fragmented pro-
grams that are now in place, leading to the creation of databases on
the accuracy of genetic testing, an important objective in the area.
A third option is to empower professional associations, such as
the American College of Medical Genetics or the American Society of
Human Genetics, to self-police the field. There are a growing number
of professional organizations becoming involved with the genetic-
testing issue. A partial list includes: the Association of Public Health
Laboratories; the American College of Medical Genetics; the College
of American Pathologists; the National Committee on Clinical Labora-
tory Standards; the Commission on Office Laboratory Accreditation;
the American Society of Human Genetics; the Working Group on Eth-
ical, Legal, and Social Implications of the Human Genome Project;
and the National Advisory Council for Human Genome Research. 1
6 1
These associations, through consultation with experts in the field,
could set guidelines for genetic testing. Or perhaps a group similar in
membership to the now-disbanded SACGT could be formed as a certi-
fication board, and it could be tasked with the review and approval of
genetic tests. Merely forming this group would not, of course, over-
come the problem that SACGT failed to solve: creating an actual eval-
uation system. Whether the system would mirror the current FDA
process or assume another identity entirely still needs to be ad-
dressed-as does the creation of a framework that would give these
groups legal authority to regulate. This option would likely only func-
tion if it were derived from federal or state statutes.
Assuming enhanced regulatory oversight of genetic tests can be
achieved, timing then becomes a critical issue. Due to rapid advance-
ments in the field, a regulatory system could become obsolete-or at
160. See supra note 100 for further discussion on this point. In regards to FDA's
budget, it is worth noting that
the Agriculture Department, which focuses on a far narrower range of products
and activities, is ten times larger in personnel and fifty times larger in budget. The
Army Corps of Engineers has a budget three times that of the FDA; NASA's
budget is about a dozen times larger .... [FDA's] chief failures to this day result
from the lack of people and resources to carry out the tasks mandated.
HILTS, supra note 49, at 15.
161. See Cunningham, supra note 19, at 37; Sternesky, supra note 10 at 1.
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least ineffective-in a very short period of time. It remains clear that
genetic testing has a rich future, but that future might require a pe-
riod of waiting for the "research stage" 162 of the genetic-testing sci-
ence life cycle to end. When this ending will come is impossible to
predict. Simply put, is there enough knowledge within this field to
institute an effective regulatory framework right now, or is it impru-
dent to do so? It seems clear that the home-brew issue must be ad-
dressed now, either through a wholesale reclassification of genetic
tests as medical devices or through a movement to sweep home-brews
under the umbrella of medical devices. But what about other aspects
of genetic testing?
On a high level, at least something is apparent. While each op-
tion for oversight has its proponents and detractors, there seems to be
unanimity in the scientific community on one point: physicians must
become educated on genetics. 163 Increased oversight and vigilance by
third parties are useless gestures without informed care options from
a qualified physician. Thus, as to this regard, the American College of
Medical Genetics has recommended that only health care profession-
als should be authorized to order and receive genetic test results. 164
Patients should not be granted direct access to genetic tests,'165 as they
must be educated on probabilities and the levels of doubt associated
with the process. 166
162. See Quintana-Trias, supra note 4, at 17.
163. See Weiss, supra note 20 at Al. "A 1995 survey found that one-third of medical
schools still did not require course work in genetics. And a 1997 study of 177 patients who
underwent testing for an inherited colon cancer gene found that doctors misinterpreted
the results about one-third of the time." Id.
164. Letter from R. Rodney Howell, President, American College of Medical Genetics,
to D. Joe Boone (June 30, 2000), in ACMG Lab Practice Community Announcement,
http://genetics.faseb.org/genetics/acmg/announce/lab-announce4.htm (last visited Aug.
17, 2006).
165. Id.
166. See Weiss, supra note 20 at Al. This might be more difficult than it appears. For
example, a recent British study analyzed stroke victims' consent processes, revealing that
thirty-nine percent of the patients surveyed did not know that one in four was a twenty-five
percent reduction. Letter from Simon J. Ellis et al. to the Editors (Jan. 13, 2001), in In-
formed Consent Is flawed, 357 LANCET 149, 150 (2001) (citing National Institute of Neurological
Disorders and Stroke rt-PA Stroke Study Group, Tissue Plasminogen Activator for Acute Ischaemic
Stroke, 333 NEw ENG.J. MED. 1581-87 (1995)). "44% did not know that a reduction of 25%
was a reduction of a quarter; and 43% did not know that a reduction of 25% was equivalent
to a reduction of 25 in 100." Id. The report concluded that "[a] substantial minority of
people in this population ... could not process simple statistical information .... Id.
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VI. Criticism of Increased Regulatory Oversight
Detractors of the call for increased regulation point to several fac-
tors. First, they note that increased regulation will provide no guaran-
tee of improved quality. 167 Errors still occur with blood testing that
has been widely available for decades.1 68 This testing is currently sub-
ject to CLIA and FDA regulation. 169 But proponents of increased reg-
ulation answer that guarantees are not the goal; rather, the goal is
merely to provide or improve a certain measure of quality-just as
with the current testing systems.1 70
A second criticism is that regulation would increase the time and
costs of bringing a genetic test to the marketplace. 171 Some have ar-
gued that certain tests, such as those for rare genetic diseases, "would
not be economical to develop if FDA approval were required" and
that "the greater the level of federal oversight of those tests, the less
likely someone might be to try to develop the test."172 Recent publicity
regarding FDA has not been helpful. It merely reinforces the idea that.
FDA's approval process is "notorious for its slow pace and bureau-
cracy"173 and that its close ties to the food and pharmaceutical indus-
tries destroy its objectivity. 174
Regardless of the possible veracity of these perceptions, they can-
not serve to detract from imposition of a regulatory system. While
FDA's reputation has suffered setbacks in recent times, any weak-
167. See CMS INITIATIVES TO IMPROVE QUALITY OF LABORATORY TESTING UNDER THE
CLIA PROGRAM (2006), available at http://www.cms.hhs.gov/CLIA/downloads/
060630.Backgrounder.rlEG.pdf; James 0. Westgard et al., Final Rule vs. Final Word on Qual-
ity (May 2004), available at http://www.westgard.com/essay62.htm.
168. See Associated Press, Red Cross Hit with $4.2 Million Blood Fine (Sept. 8, 2006),
available at http://www.cnn.com/2006/HEALTH/09/08/redcross.blood.ap/index.html;
Mothers Recalled over Blood Tests (Aug. 31, 2006), available at http://news.bbc.co.uk/l/hi/
England/south yorkshire/5301486.stm; M. P. Busch et al., False Negative Testing Errors in
Routine Viral Marker Screening of Blood Donors for the Retrovirus Epidimology Donor Study, 40
TRANSFUSION 585 (2000).
169. See Blood Products Advisory Committee, http://www.fda.gov/cber/advisory/ bp/
bp06Ol.htm (last visited Aug. 17, 2006).
170. See supra Part V.
171. See Mark B. McClellan, FDA: Protecting and Advancing America's Health, 14 HEALTH
MATRIX 357, 365 (2004). "[D]evelopers of new medical products that are designed to treat
serious illnesses increasingly need to set aside billions of dollars or redirect their research
activities from potentially valuable directions in anticipation of the potentially unlimited
risk of mass tort lawsuits." Id.; see also Epps, supra note 6.
172. Pollack, supra note 91, at C2.
173. Epps, supra note 6.
174. See Richard Horton, Commentary, Lotronex and the FDA: A Fatal Erosion of Integrity,
357 LANCET 1544, 1544 (2001); see also Kellman, supra note 90.
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nesses in its architecture must be addressed, regardless of the issues
involving regulatory oversight of genetic testing.
Finally, some have remarked that the law often serves as a blunt
instrument.1 75 With a field as fraught with uncertainty as genetics, 76
perhaps the law should be fashioned to function as a surgical probe or
scalpel, rather than a police baton. However, to the extent it functions
in that manner, perhaps a more important question needs to be ad-
dressed: When should laws ever be made? How much evidence of
abuse must be gathered and documented before a more robust regu-
latory system is implemented?
VII. Conclusion
As early as 1997, clear concerns were being voiced for genetic
testing:
Science may outstrip public health policy ... and policy decisions
made as a "knee jerk" reaction may impede access to medical
care; ... [plolicy decisions may be made by individuals with narrow
fiscal interests;... [a] ctions by certain groups may exceed reasona-
ble interventions and cause emotional reactions in the scientific
and public policy communities; and . . . [p]atients and practition-
ers will be faced with information overload .... 177
But undeniably, the power and significance of genetic informa-
tion in society continues to grow. 178 The recent passage, in the United
States Senate, of the Genetic Information Nondiscrimination Act at-
tests to this. 179 Thus, it has become increasingly evident that-regard-
less of the composition of the ultimate regulatory scheme for genetic
testing-the regulations will need to anticipate the future of the sci-
ence and undergo frequent analysis to ensure they are keeping pace
with the expansion. 180
175. Interview with Sara Rosenbaum, Professor, The George Washington University
School of Law (discussing how legal scholars have described the use of law).
176. SeeJavitt et al., supra note 1, at 263, 265.
177. CTRS. FOR DISEASE CONTROL, SUBCOMMITTEE MEETING ON GENETICS 3 (1997), avail-
able at http://www.phppo.cdc.gov/CLIAC/pdf/gsc997.pdf.
178. See Genetic Information Nondiscrimination Act, S. 1053, 108th Cong. (2003)
("[A]dvances in genetics open major new opportunities in medical progress.").
179. See Genetic Information Nondiscrimination Act, S. 306, 109th Cong. (2005); Brian
DeBose, Senate Votes to Ban Bias Based on Genetic Makeup, WASH. TIMES, Feb. 18, 2005, availa-
ble at http://www.washingtontimes.com/functions/print.php?StorylD= 20050217-114810-
9747r.
180. See Sternesky, supra note 10, at 2.
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At some point, the government must intervene in the current
scheme and provide increased oversight of genetic testing.' 8' Again,
when this should actually occur is still an open question. It rightly
offends the sensibilities of qualified clinicians to have the doctor-pa-
tient relationship so thoroughly co-opted by directly marketed genetic
tests. Yet, there are not, at least at this point, parades of abuses arising
in the media and elsewhere that highlight any negative impact the
commercial laboratories are having on an unsuspecting public. But
why should society wait for the negative impacts to mount before plan-
ning a solution?
The current disparate regulatory structure provides little neces-
sary protection to consumers and patients. By increasing the resources
of FDA and charging the agency with total oversight of genetic testing,
efficiencies of scale and scope could be realized. As the sole overseer
of genetic testing, FDA would be equipped to determine where the
cracks in the armor of genetic regulation are and to fix those cracks. A
good place to begin would be with the adoption of CLIAC and
SACGT's recommendations. They contain the fruits of much work by
genetic experts and provide an excellent foundation for a specific
genetic-testing regulatory system.
Genetic testing is already within the radar of Mark McClellan, the
current Commissioner of FDA. His strategic plan lists as one of its first
objectives: "Direct agency research programs and develop standards to
effectively handle emerging technologies, especially in areas of
pharmacogenomics, gene therapy, and combination devices" in order
to achieve the goal of "more efficient and rapid translation of new
scientific developments and breakthroughs into safe and effective
medical products."182
181. The United States is not alone in this regard. From an international standpoint,
European countries are also seeking to address the issue of quality assurance and regula-
tions for genetic testing. But they, too, have yet to settle on a format. See Cox, supra note
157, at 178, 179. "[T ] he European Thematic Network for Cystic Fibrosis and the European
Genetics Quality Network . . . have supported external quality assessment schemes and
development of 'best-practices' protocols through the consensus process among its inter-
national participants." Id.
There are more than 400 laboratories in the networks. "Thus, there has been wide
acknowledgement among the international community that genetic testing requires addi-
tional measures to assure quality in laboratory practices and that this can be achieved by a
combination of enhanced regulatory oversight, adherence to recommendations developed
by professional organizations, and participation in voluntary quality assurance programs."
Id. "An internationally recognized accreditation system for genetic testing laboratories
does not yet exist." Id. at 180.
182. See AcFION PLAN, supra note 54.
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Thus, the tide may be slowly turning to a unified regulatory strat-
egy, but it must turn with some alacrity, as advances in the field are
not waiting for federal oversight efforts to catch up. Because FDA al-
ready regulates most laboratory tests as medical devices, the transition
should, not be difficult when the appropriate time comes. Only "with
adequate quality assurance and education about the meaning of the
results"183 can we achieve the rich potential of genetic tests-the abil-
ity to effectively realize the meaning of the phrase "planning for the
future."184
183. See Epps, supra note 6.
184. See id.
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